BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38118318)

  • 21. Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread.
    Leal JN; Gonen M; Covey AM; Erinjeri JP; Getrajdman G; Sofocleous CT; D'Angelica M; DeMatteo RP; Abou-Alfa GK; Jarnagin WR; Fong Y; Brown KT
    J Vasc Interv Radiol; 2015 Aug; 26(8):1112-21. PubMed ID: 26038273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases.
    Katamura Y; Aikata H; Kimura Y; Kawaoka T; Takaki S; Waki K; Hiramatsu A; Kawakami Y; Takahashi S; Ishikawa M; Hieda M; Kakizawa H; Chayama K
    J Gastroenterol Hepatol; 2010 Jun; 25(6):1117-22. PubMed ID: 20074168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib.
    Chang WI; Kim BH; Kim YJ; Yoon JH; Jung YJ; Chie EK
    J Gastroenterol Hepatol; 2022 Feb; 37(2):387-394. PubMed ID: 34693560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
    Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
    Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy.
    Shao YY; Wu CH; Lu LC; Chan SY; Ma YY; Yen FC; Hsu CH; Cheng AL
    J Hepatol; 2014 Feb; 60(2):313-8. PubMed ID: 24036008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
    Abdel-Rahman O; Abdelwahab M; Shaker M; Abdelwahab S; Elbassiony M; Ellithy M
    J Egypt Natl Canc Inst; 2014 Mar; 26(1):9-13. PubMed ID: 24565677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of intrahepatic progression patterns of hepatocellular carcinoma and colorectal liver metastases following CT-guided high dose-rate brachytherapy.
    Xu H; Schmidt R; Hamm CA; Schobert IT; He Y; Böning G; Jonczyk M; Hamm B; Gebauer B; Savic LJ
    Ther Adv Med Oncol; 2021; 13():17588359211042304. PubMed ID: 34539817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
    Hong YM; Yoon KT; Cho M
    BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
    Pan Y; Mei J; Chen J; Zhang D; Wang J; Wang X; Yi M; Zhou Z; Zhang Y; Chen M; Guo R; Xu L
    Ann Surg Oncol; 2022 Mar; 29(3):2016-2029. PubMed ID: 34637058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis.
    Duan F; Wang MQ; Liu FY; Wang ZJ; Song P; Wang Y
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):156-63. PubMed ID: 22524574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeated Carbon-Ion Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma.
    Tomizawa K; Shibuya K; Shiba S; Okazaki S; Miyasaka Y; Oishi M; Okamoto M; Ohno T
    Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1100-1109. PubMed ID: 36870514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
    Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
    Oh MJ; Lee HJ; Lee SH
    Clin Mol Hepatol; 2013 Sep; 19(3):288-99. PubMed ID: 24133667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma.
    Mei J; Li SH; Wang QX; Zhong XP; Lu LH; Kan A; Wei W; Guo RP
    Cancer Med; 2020 Jan; 9(1):62-76. PubMed ID: 31701652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
    Zhang W; Zhang K; Liu C; Gao W; Si T; Zou Q; Guo Z; Yang X; Li M; Liu D; Mu H; Li H; Yu H; Xing W
    Front Immunol; 2023; 14():1127349. PubMed ID: 37180098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
    Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
    Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
    Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic artery intervention combined with immune-targeted therapy is superior to sequential therapy in BCLC-C hepatocellular carcinoma.
    Dong H; Jian Y; Wang M; Liu F; Zhang Q; Peng Z; Cheng N; Zhang W
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5405-5416. PubMed ID: 36454282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
    Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
    Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.